头孢哌酮钠舒巴坦钠联合莫西沙星治疗重症肺炎临床疗效观察

The Value of Cefoperazone Sodium and Sulbactam Sodium for Injection Combined with Moxifloxacin Hydrochloride on Severe Pneumonia

目的:研讨重症肺炎患者应用注射用头孢哌酮钠舒巴坦钠与盐酸莫西沙星联合治疗的临床价值。方法:选取福建省老年医院2019年5月至2020年8月收治的79例重症肺炎患者纳入本研究,遵从"计算机随机分组法"将其分为对照组(42例,注射用头孢哌酮钠舒巴坦钠常规治疗)和观察组(37例,注射用头孢哌酮钠舒巴坦钠联合盐酸莫西沙星治疗),观察两组患者临床疗效、退热时间、治疗前后炎症因子水平以及生活质量改善情况。结果:观察组患者治疗总有效率高达97.2%,对照组仅有83.3%,组间比较,差异具有统计学意义(P<0.05)。治疗后,观察组患者机械通气时间、退热时间及咳痰、肺部啰音消失时间均较对照短,差异具有统计学意义(P<0.05)。治疗后,观察组患者白细胞介素(IL)-2、IL-4以及C反应蛋白(CRP)水平均低于对照组,差异具有统计学意义(P<0.05)。治疗后,观察组患者生理机能、情感职能、社会功能等生活质量评分均较对照组高,差异具有统计学意义(P<0.05)。结论:采用注射用头孢哌酮钠舒巴坦钠与盐酸莫西沙星联合治疗方案对重症肺炎患者实施治疗,可缩短退热时间、提高临床疗效的同时提升患者生活质量。

Objective To study the clinical value of combined treatment of cefoperazone sodium and sulbactam sodium for injection and moxifloxacin hydrochloride in the treatment of patients with severe pneumonia.Methods A total of 79 patients with severe pneumonia admitted to Fujian Provincial Geriatric Hospital from May 2019 to August 2020 were included in this study,and they were divided into a control group(42 cases,cefoperazone sodium and sulbactam for injection)according to the"computer randomization method"Conventional sodium treatment)and observation group(37 cases,cefoperazone sodium and sulbactam sodium for injection combined with moxifloxacin hydrochloride);observe the clinical efficacy,antipyretic time,inflammatory factors before and after treatment,and the improvement of quality of life.Results The total effective rate of treatment in the observation group was as high as 97.2%,while that in the control group was only 83.3%.The difference between the groups was statistically significant(P<0.05).After treatment,the observation group of patients with antimicrobial treatment,mechanical ventilation,antipyretic time and the disappearance of sputum and lung rales were all shorter than those in the control group,and the difference was statistically significant(P<0.05).After treatment,the levels of interleukin(IL)-2,IL-4 and C-reactive protein(CRP)in the observation group were lower than those in the control group,and the difference was statistically significant(P<0.05).After treatment,the quality of life scores of patients in the observation group,such as physiological function,emotional function,and social function,were higher than those in the control group,and the difference was statistically significant(P<0.05).Conclusion To implement drug treatment for patients with severe pneumonia,it is recommended to use the combined treatment of cefoperazone sodium and sulbactam sodium for injection and moxifloxacin hydrochloride,which can shorten the antipyretic time,improve the clinical efficacy and improve the quality of life of the patients.